Editor’s note: This is a developing news story. Please check back soon for updates.
The phase 3 COAST trial investigating 2 mg sozinibercept for the treatment of wet age-related macular degeneration in combination with 2 mg aflibercept did not meet its primary endpoint, according to a press release from Opthea.
As Healio previously reported, the study enrolled more than 990 patients with wet AMD, with a primary endpoint of mean change in best corrected visual acuity from baseline to week 52.
In patients with minimally classic and occult lesions who (Read more...)